Abstract Tumors can evade natural killer (NK) cells by activating inhibitory pathways. We therefore have developed a highly efficient CRISPR/Cas9-based method for editing the genome of peripheral blood human NK cells (PB-NKs) to knock out ADAM17 and PD1 or knock-in genes using recombinant AAV6. Our method allows editing of PB-NKs at efficiencies reaching 90%, equivalent to methods reported for primary human T cells. Moreover, we demonstrate that ADAM17 and PD1 KO PB-NKs have significantly improved activity, cytokine production, and cancer cell cytotoxicity. Our platform represents a feasible method for generating engineered NK cells as a universal therapeutic for cancer immunotherapy.
Introduction
Natural killer (NK) cells are critical components of the innate immune system due to their ability to kill a variety of target cells, including cancer cells. Killing of targets by NK cells is mediated by the integration of signals from activating and inhibitory receptors and cytokines 1 . The ability of NK cells to kill tumor cells, along with the ease with which they are isolated and expanded from peripheral blood, has made them an attractive source for immunotherapy 2, 3 . Moreover, as they do not induce graft versus host disease 4 , they can be generated from unrelated donors and, therefore, represent an 'off the shelf' therapeutic cell type. However, NK cell immunotherapy has seen limited success in the clinic, due in part to their lack of persistence and expansion after transplant 5 .
Changes in NK cell receptor repertoire and ligand expression in the tumor microenvironment can also lead to decreased NK cell activity 6, 7 .
One potent activator of NK cells is CD16a (FCγRIIIa), which binds the Fc portion of IgG-coated target cells. This antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells underlies the effectiveness of anti-tumor therapeutic antibody treatment of malignancies 8, 9 . After activation, CD16a is rapidly cleaved from the cell surface by A Disintegrin And Metalloproteinase-17 (ADAM17), resulting in attenuated activity. Chemical inhibition of ADAM17 leads to increased cytokine production by human NK cells 10 , suggesting that the use of monoclonal antibodies combined with inhibition of ADAM17 could enhance the anti-tumor response.
Various cells within the tumor micro-environment also secrete immunosuppressive molecules that interfere with the complex array of receptors that regulate NK cells and their ability to expand 12 .
For example, some tumor cells upregulate PD-L1, which engages PD1 on NK cells reducing cytotoxic activity 13, 14 . This inhibition imposed on NK cells is a limiting factor in effective NK immunotherapy and overcoming this immunosuppression is necessary for viable therapeutic development. Strategies for overcoming these challenges have focused on releasing NK cell inhibition through the use of pharmaceutical inhibitors and monoclonal antibodies [15] [16] [17] . However, there are limitations to these strategies: off-target toxicity is common with these types of therapies and, importantly, no humanized antibodies or chemical inhibitors exist for some high interest targets.
An alternative approach is to use CRISPR/Cas9 to edit genes relevant to NK function in order to improve their utility as an immunotherapeutic agent. Changes made with this approach are confined to NK cells, reducing undesirable systemic effects. Additionally, design and optimization of CRISPR guide RNAs (gRNAs) is straightforward and cost-effective, making it easy to target any gene of interest. Here, we present the development of an approach for achieving high rates of gene editing in activated primary human NK cells combined with expansion to clinically relevant numbers and show that gene edited NK cells have enhanced function in vitro and in vivo. Our method is capable of knocking-out genes at rates up to 90% and knocking in genes at rates up 79%.
In summary, we present a rapid platform for generating high functioning genetically modified NK cells for use in cancer immunotherapy.
Materials and Methods

Donor NK Cell Isolation and Expansion
Peripheral blood mononuclear cells (PBMCs) from de-identified healthy human donors were obtained by automated leukapheresis (Memorial Blood Centers, Minneapolis, MN) and further isolated on a ficoll-hypaque (Lonza) gradient. CD56+CD3-NK cells were isolated by negative selection using the EasySep Human NK Cell Enrichment Kit (Stemcell Technologies). After isolation, NK cells were either rested by culture with 1 ng/mL IL15, or activated by co-culture with Clone9.mbIL21 at a 2:1 or 1:1 (feeder:NK) ratio in B0 supplemented with 50 IU/mL IL2 (Peprotech), as described 18 . Samples were obtained after informed consent with approval from the University of Minnesota Institutional Review Board (IRB 1602E84302).
Cell Culture
NK cells were maintained in B0 medium 19 supplemented with 1 ng/mL IL15 unless otherwise noted. NK cells were cryopreserved at 1x10 7 cells/mL in CryoStor CS10 (Sigma Aldrich). The Guide RNA design gRNAs targeting ADAM17, PD1, CISH, and AAVS1 were designed using the CRISPR MIT webtool (http://crispr.mit.edu.ezp1.lib.umn.edu/) along with Cas-OFFinder. Six gRNAs per target gene were tested in HEK293T cells and the most efficient gRNA (see Table 1 ) was then ordered from TriLink Biotechnologies or Synthego with 2'-O-methyl and 3' phosphorothioate modifications to the first three 5' and the last three 3' nucleotides. 
Electroporation of activated NK cells
Activated NK cells were pelleted and resuspended at 3x10 7 cells/mL in T buffer (Neon Transfection System Kit, ThermoFisher Scientific). 1.5 ug Cas9 mRNA (Trilink) and 1 ug chemically-modified guide RNA (Trilink or Synthego) were added to 10 uL (3x10 5 cells) on ice.
Cas9 mRNA alone, without guide RNA, was used as a control for all experiments. This mixture was electroporated with the Neon Transfection System (ThermoFisher Scientific) using 2 pulses of 1850 volts and 10 ms pulse width. NK cells were recovered in warm B0 medium containing 1 ng/mL IL15. For rAAV6 infection, rAAV6 (MOI=500,000) was added to NK cells 30 minutes after electroporation. rAAV6 particles were produced by the University of Minnesota Vector Core.
Analysis of gene editing efficiency
PCR primers were designed to amplify a 400-500 bp region surrounding the gRNA target site ( 
RT-PCR
RNA was extracted using the PureLink RNA Mini Kit (Ambion). cDNA was generated using the Transcriptor First Strand cDNA Synthesis Kit (Roche). Real-time PCR was conducted using intron-spanning primer sets ( Table 2 ) and SYBR Green Master Mix (Applied Biosystems) and
analyzed using a CFX-96 (Bio-Rad). Gene expression levels were calculated relative to -actin.
Western blot
Cells were lysed in RIPA buffer (Sigma) supplemented with phosphatase inhibitors (Sigma) and protease inhibitors (Roche) for 30 min and purified by centrifugation (14,000 x g for 15 min).
Concentration of the protein lysate was determined by BCA (Pierce). All samples and reagents were prepared according to the SimpleWestern manual for Wes (ProteinSimple). Samples were diluted to equal concentration (750 ng) with 0.1X Sample Buffer (ProteinSimple) and combined with 0.2 mg/mL 5X Fluorescent Master Mix (ProteinSimple). Final samples were denatured at 95C for 5 minutes. The provided microplate containing separation and stacking matrices was loaded with biotinylated ladder (ProteinSimple), blocking reagent, primary antibody (B-actin (Cell Signaling Technologies) 1:100; CISH (Cell Signaling Technologies) 1:50; antibodies were diluted using provided diluent), Secondary HRP conjugate, chemiluminescent luminol-peroxide mix, and wash buffer. The self-regulating protocol of the SimpleWestern system was followed and data was analyzed using the Compass Software (ProteinSimple).
Antibodies and Flow Cytometry
The 
NK Cell Functional Assays
For PMA stimulation, NK cells were pre-treated for 1 hour with 10 uM ADAM17 inhibitor Friday for 3 weeks. Animal health was monitored daily and mice were euthanized when moribund.
Statistical Analysis
The Student's t test was used to test for significant differences between two groups. Differences between more than 2 groups were tested by one-way ANOVA analysis with Tukey post-hoc test for multiple comparisons. All in vitro assays were repeated in 3-5 independent donors. Mean values +/-SEM are shown. In vivo data was generated using n=10 mice per group. Overall survival was calculated using Kaplan-Meier methods and treatment groups were compared using log rank tests. P values < 0.05 were considered statistically significant. Statistical analyses were performed using GraphPad Prism 6.0.
Results and Discussion
To improve NK cell cytotoxicity, we developed an optimized CRISPR/Cas9 system capable of disrupting important regulatory genes in activated primary human NK Cells. Based on our previous work with primary human T cells and B cells, we hypothesized that activating NK cells prior to electroporation would make them more amenable to nucleic acid delivery 21, 22 . To test this, we delivered nucleic acid in the form of eGFP mRNA to NK cells isolated from peripheral blood mononuclear cells (PBMCs) using protocols with resting or activated NK cells. We found that NK cells activated with irradiated feeder cells expressing membrane-bound IL21 (Clone9.mbIL21, C9s) 18 and cultured with IL-2 for 7 days prior to electroporation resulted in the most efficient nucleic acid delivery and NK cell viability (Figure 1A) . Using this approach, we routinely achieve >98% transfection efficiency with >90% cell viability (Supplemental Figure 1A) . Importantly, C9-expanded NK cells have been used clinically and have been shown to be safe and effective for multiple myeloma patients 23 .
Using our optimized protocol we delivered Cas9 mRNA alone as a control, or in combination with synthetic chemically modified gRNAs 24 targeting ADAM17 11 , PD1 14 , and CISH 25 to C9 activated NK cells. We were able to achieve gene editing efficiency of 80.9  9.9% for ADAM17, 81.9  7.4% for PD1, and 67.6  14.1% for CISH without the use of any enrichment methods. (Figure   1B) . We compared next generation sequencing (NGS) and Tracking of Indels by Decomposition (TIDE) analysis to quantify gene editing efficiency across five independent donors in which we knocked out ADAM17, PD1, or CISH. The TIDE web tool quantifies indel formation using Sanger sequencing reactions 26 . We observed no significant difference between editing efficiency calculated using TIDE versus NGS (Supplemental Figure 1G) . Critically, these editing events were maintained at similar frequencies after multiple rounds of expansion using C9 feeders ( Figure 1C) and did not affect our ability to expand cells to clinically relevant numbers ( Figure   1D ). Protein expression of targeted genes was also significantly decreased by 89.8  1.2% for ADAM17, 82.7  8.6% for PD1, and 91.9  14.0% for CISH, and mRNA expression followed a similar pattern (Figure 1E-G; Supplemental Figure 1B-F) . Furthermore, with the goal of developing "off-the-shelf" clinical products we sought to optimize cryopreservation of activated and gene-edited NK cells. Previous groups have shown low NK cell recovery and cytotoxicity after cryopreservation 27 . We found that freezing 1x10 7 NK cells per mL using CryoStor CS10 preservation media yielded ~80% recovery after thaw, and that gene editing did not affect this process (Supplemental Figure 1H) .
In addition to successful gene knock-out (KO), we adapted our method for gene knock-in (KI) by co-delivering a DNA template for homologous recombination (HR) using rAAV6 along with Cas9 and gRNA. As proof-of-principle, we delivered Cas9 and gRNA targeting the AAVS1 locus downstream of the endogenous promoter/splice donor. Co-delivery of a promoter-less EGFP targeting vector in rAAV6 resulted in successful HR in 77.2  3.0% of NK cells based on EGFP expression (Figure 1H and 1I) . Together, these data demonstrate that high-efficiency Cas9mediated gene KO and KI is achievable in activated primary human NK cells.
ADAM17 is responsible for the rapid cleavage of the activating Fc-gamma receptor CD16a from the surface of NK cells after activation 11, 28 , resulting in inhibition of NK cytotoxicity. Chemical inhibitors of ADAM17 are currently in clinical trials in combination with antibody treatments as a method of enhancing the therapeutic effect of NK cells (NCT02141451). We reasoned that targeting ADAM17 directly in the NK cell could avoid systemic toxicities associated with offtarget effects of chemical inhibitors. Using an artificial activation system (PMA) 11 we demonstrate that ADAM17 KO NK cells maintain significantly higher surface expression of CD16a compared to control NK cells (which received Cas9 mRNA alone) and are on par with what is observed when NK cells are pre-treated with the ADAM17 inhibitor INCB007839 (Figure 2A; Supplemental   Figure 3A ). Surface membrane levels of CD62L, an additional target of ADAM17 11, 29 , are also undiminished in activated ADAM17 KO NK cells (Supplemental Figure 3B) . To test if ADAM17 KO NK cells have enhanced ADCC we performed standard ADCC assays using the CD20-positive Burkitt's lymphoma cell line Raji. Raji cells were pre-treated with Rituximab, a monoclonal antibody targeting CD20. Rituximab-coated Raji cells induced cleavage of CD16a in 79.5  1.3% of control NK cells, but there were no differences in CD16a cleavage in ADAM17 KO NK cells (Figure 2B; Supplemental Figure 3C) . Moreover, while no significant difference was observed in cytotoxic degranulation (Figure 2C; Supplemental Figure 3D ) ADAM17 KO NK cells displayed a significant increase in IFN production (Figure 2D; Supplemental Figure   3E ). Importantly, ADCC was significantly enhanced when using ADAM17 KO versus control NK cells based on increased apoptosis as measured by cleaved Caspase 3 expression of Rituximabcoated Raji cells. (Figure 2E; Supplemental Figure 3F ). This finding contrasts with results using the clinically approved ADAM17 inhibitor, which did not lead to enhanced killing of Rituximabcoated Raji cells in previous reports 11 . Taken together, these data demonstrate that genetic KO of ADAM17 in NK cells blocks CD16a shedding comparable to ADAM17 inhibitors and leads to enhanced ADCC, not seen with current inhibitors of ADAM17.
NK cells are also capable of target cell killing independent of ADCC, through direct interaction between activating receptors on NK cells and cell surface proteins on target cells. However, tumor cells can block this cytotoxicity by inducing NK cell inhibitory signals through cell-surface protein
interactions such as PD-L1:PD1 13, 14 . We used our gene-editing method to generate PD1 KO NK cells and tested their ability to directly kill four cancer cell lines compared to control NK cells that were electroporated with Cas9 mRNA only. We selected four cancer cell lines with various expression levels of PD-L1 (Supplemental Figure 4A )the chronic myeloid leukemia line K562 (PD-L1 low), the acute monocytic leukemia line THP1 (PD-L1 high), the prostate carcinoma line DU145 (PD-L1 high), and the ovarian carcinoma line MA148 (PD-L1 low). In a co-culture killing assay, PD1 KO NK cells had significantly higher levels of degranulation (Figure 3A; Supplemental Figure 4B ) and production of IFN (Figure 3B; Supplemental Figure 4C ).
Similar to our ADCC results, PD1 KO NK cells also led to increased apoptosis of target cells compared to all controls (Figure 3C; Supplemental Figure 4D ). To test functionality in vivo, we used PD1 KO NK cells to treat an orthotopic mouse xenograft model of ovarian cancer 30 PD-L1 expression significantly increased over time after transplant and subsequent treatment with activated NK cells (Figure 3G) . We also assessed PD-L1 expression on MA148 ascites tumors at the time of necropsy from mice in all treatment groups (Figure 3H) Overall, we observed significantly higher PD-L1 expression on MA148 cells from mice treated with activated NK cells.
These data are consistent with the hypothesis that the inflammatory environment created by activated NK cells increases PD-L1 expression on tumor cells and underlies the need for creating PD1-deficient NK cells for cancer therapy.
CISH has been identified as a negative regulator of IL-15 signaling in murine NK cells, and its deletion has been shown to enhance their proliferation, activation, and tumor cell killing 25, 31 . To determine whether CISH serves as a similar checkpoint in human NK cells, we performed assays for proliferation, activation, and tumor cell killing using CISH KO NK cells. In co-culture experiments with K562 or MA148 target cells, CISH KO NK cells did not have enhanced degranulation, cytokine production, or tumor cell killing (Supplemental Figure 2A-C) . However, we did observe enhanced proliferation of CISH KO NK cells in response to low doses of IL-15 (Supplemental Figure 2D and 2E) . These data emphasize the importance of validating results from murine NK cell experiments in human NK cells as significant differences have been previously reported between murine and human NK cells. These include expression of defining markers and signaling molecules 32 , localization to lymph nodes 33 , and cytotoxic capabilities 34 . Our data suggest that although CISH may be an important checkpoint in murine NK cells, it does not dampen antitumor immunity in human NK cells in vitro. Alternatively, the activated nature of our NK cells, due to our expansion culture conditions, could be superseding the normal regulatory effects of CISH in human NK cells.
NK cell immunotherapy holds great promise as an off-the-shelf cell therapy that does not require antigen specificity. Our work demonstrates the feasibility of generating clinical quantities of geneedited NK cells with enhanced cytotoxic capabilities. We are able to effectively alter inhibitory protein expression in activated NK cells isolated from PBMCs. In vitro and in vivo assays demonstrate that these NK cells are capable of enhanced killing through ADCC and non-ADCC pathways. Future work will focus on methods of editing multiple genes simultaneously along with delivery of engineered receptors, similar to chimeric antigen receptors used in T cell therapy, for enhancing NK cell immunotherapy. If successful, these highly engineered, allogeneic NK cells could rival current autologous CAR-T cell therapies at a greatly reduced cost. 
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